NorthCrest Asset Manangement LLC lowered its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 30.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 38,951 shares of the biopharmaceutical company's stock after selling 17,115 shares during the quarter. NorthCrest Asset Manangement LLC's holdings in Pfizer were worth $1,033,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer during the 4th quarter worth $27,000. Gould Capital LLC raised its stake in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the 4th quarter worth $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Analysts Set New Price Targets
PFE has been the subject of several research reports. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and a consensus price target of $29.17.
Read Our Latest Research Report on Pfizer
Pfizer Trading Up 0.0%
PFE traded up $0.01 during midday trading on Friday, hitting $23.46. The company's stock had a trading volume of 56,576,195 shares, compared to its average volume of 41,238,982. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $133.38 billion, a P/E ratio of 16.64, a PEG ratio of 0.64 and a beta of 0.58. The firm has a 50-day moving average price of $23.12 and a two-hundred day moving average price of $25.07. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.82 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.33%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is currently 124.64%.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
